Cybin's Helus Pharma to join three investor conferences in New York in September 2026

Cybin Inc., operating under the commercial name Helus Pharma, disclosed in a series of 6-K filings that its Chief Executive Officer, Michael Halstead, will appear at three separate investor conferences in New York City during September 2026.

The first is the Cantor Global Healthcare Conference, where Halstead will participate in a fireside chat at the conference taking place September 9-11, 2026¹. That session is set to be webcast live on Friday, September 11, 2026 at 8:00 a.m. EDT¹.

Next, Helus Pharma said Halstead will take part in a fireside chat at the "H.C. Wainwright 28th Annual Global Investment Conference," which the company said is taking place September 14-16, 2026². That chat is scheduled to be webcast live on Monday, September 14, 2026 at 9:00 a.m. EDT².

Finally, at the Morgan Stanley 24th Annual Global Healthcare Conference, Halstead is set to appear in a fireside chat webcast live on Wednesday, September 16, 2026 at 8:30 a.m. EDT³.

Each filing describes Helus Pharma as the commercial operating name of Cybin Inc., a clinical stage pharmaceutical company focused on developing serotonergic agonists intended to activate serotonin pathways believed to support neuroplasticity³. The company said its pipeline includes HLP003, which it describes as being in Phase 3 clinical development for the adjunctive treatment of major depressive disorder and has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration³, alongside HLP004, which is in Phase 2 for generalized anxiety disorder³. The company added that it operates in Canada, the United States, the United Kingdom, and Ireland³. Replays of each webcast are expected to be posted on the company's investor relations site.